Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Drug Review Europe Regulation

New Filings At The EMA

  • News

Executive Summary

New medicines under evaluation at the European Medicines Agency.

You may also be interested in...



Allergan Declines To Confirm Abicipar Pegol Fate

There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.

First Ophthalmic Formulation Of Bevacizumab Among New Filings At EMA

Using the cancer drug off-label to treat wet AMD has been controversial.

New EU Filings

Santhera Pharmaceuticals’ vamorolone for treating Duchenne muscular dystrophy is among the latest medicines that have been submitted for review for potential pan-EU approval.

Table

View full table

Topics

Tags:
Drug Review Europe Regulation
Latest News

Medicare CED Update Targets Study ‘Efficiency,’ But May Not Ease Data Collection Burden

US Supreme Court Preview: ‘Skinny’ Labels, FTC, And FCA – But No Tecfidera As Biogen Loses Bid

In-Person US FDA Meetings Returning? Agency Will Support Those Events At HQ

US FDA Still Hasn’t Decided Who Will Be Final Arbiter On Approval Status For Covis’ Makena

See All
UsernamePublicRestriction

Register

PS142372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By